Skip to main content
SpringerLink
Log in
Book cover

Atrial Fibrillation and Percutaneous Coronary Intervention pp 1–18Cite as

Atrial Fibrillation on Vitamin K Antagonist Undergoing Elective Percutaneous Coronary Intervention for Stable Effort Angina

  • Chapter
  • First Online:

  • 920 Accesses

Abstract

Gender: female.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   109.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.00
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Lip GY, Windecker S, Huber K, Kirchhof P, Marin F, Ten Berg JM, Haeusler KG, Boriani G, Capodanno D, Gilard M, Zeymer U, Lane D, Document Reviewers, Storey RF, Bueno H, Collet JP, Fauchier L, Halvorsen S, Lettino M, Morais J, Mueller C, Potpara TS, Rasmussen LH, Rubboli A, Tamargo J, Valgimigli M, Zamorano JL. Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm Society (APHRS). Eur Heart J. 2014;35:3155–79.

    Article  PubMed  Google Scholar 

  2. Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Jüni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A. 2014 ESC/EACTS guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J. 2014;35:2541–619.

    Article  PubMed  Google Scholar 

  3. Karjalainen PP, Vikman S, Niemelä M, Porela P, Ylitalo A, Vaittinen MA, Puurunen M, Airaksinen TJ, Nyman K, Vahlberg T, Airaksinen KE. Safety of percutaneous coronary intervention during uninterrupted oral anticoagulant treatment. Eur Heart J. 2008;29:1001–10.

    Article  PubMed  Google Scholar 

  4. Lahtela H, Rubboli A, Schlitt A, Karjalainen PP, Niemelä M, Vikman S, Puurunen M, Weber M, Valencia J, Biancari F, Lip GY, Airaksinen KE, AFCAS (Management of patients with Atrial Fibrillation undergoing Coronary Artery Stenting) study group. Heparin bridging vs. uninterrupted oral anticoagulation in patients with Atrial Fibrillation undergoing Coronary Artery Stenting. Results from the AFCAS registry. Circ J. 2012;76:1363–8.

    Article  CAS  PubMed  Google Scholar 

  5. Dewilde WJ, Janssen PW, Kelder JC, Verheugt FW, De Smet BJ, Adriaenssens T, Vrolix M, Brueren GB, Vandendriessche T, Van Mieghem C, Cornelis K, Vos J, Breet NJ, Ten Berg JM. Uninterrupted oral anticoagulation versus bridging in patients with long-term oral anticoagulation during percutaneous coronary intervention: subgroup analysis from the WOEST trial. EuroIntervention. 2015;11:381–90.

    Article  PubMed  Google Scholar 

  6. Kiviniemi T, Airaksinen KE, Rubboli A, Biancari F, Valencia J, Lip GY, Karjalainen PP, Weber M, Laine M, Kirchhof P, Schlitt A, AFCAS (Management of patients with Atrial Fibrillation undergoing Coronary Artery Stenting) study group. Bridging therapy with low molecular weight heparin in patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: the AFCAS study. Int J Cardiol. 2015;183:105–10.

    Article  PubMed  Google Scholar 

  7. Garcia DA, Crowther MA. Reversal of warfarin: case-based practice recommendations. Circulation. 2012;125:2944–7.

    Article  PubMed  Google Scholar 

  8. Pancholy SB, Ahmed I, Bertrand OF, Patel T. Frequency of radial artery occlusion after transradial access in patients receiving warfarin therapy and undergoing coronary angiography. Am J Cardiol. 2014;113:485–90.

    Article  CAS  PubMed  Google Scholar 

  9. Hamon M, Pristipino C, Di Mario C, Nolan J, Ludwig J, Tubaro M, Sabate M, Mauri-Ferré J, Huber K, Niemelä K, Haude M, Wijns W, Dudek D, Fajadet J, Kiemeneij F, European Association of Percutaneous Cardiovascular Interventions; Working Group on Acute Cardiac Care of the European Society of Cardiology; Working Group on Thrombosis on the European Society of Cardiology. Consensus document on the radial approach in percutaneous cardiovascular interventions: position paper by the European Association of Percutaneous Cardiovascular Interventions and Working Groups on Acute Cardiac Care and Thrombosis of the European Society of Cardiology. EuroIntervention. 2013;8:1242–51.

    Article  PubMed  Google Scholar 

  10. Cavender MA, Sabatine MS. Bivalirudin versus heparin in patients planned for percutaneous coronary intervention: a meta-analysis of randomised controlled trials. Lancet. 2014;384:599–606.

    Article  CAS  PubMed  Google Scholar 

  11. Briguori C, Visconti G, Focaccio A, Donahue M, Golia B, Selvetella L, Ricciardelli B. Novel approaches for preventing or limiting events (Naples) III trial: randomized comparison of bivalirudin versus unfractionated heparin in patients at increased risk of bleeding undergoing transfemoral elective coronary stenting. JACC Cardiovasc Interv. 2015;8:414–23.

    Article  PubMed  Google Scholar 

  12. Kiviniemi T, Karjalainen P, Niemelä M, Rubboli A, Lip GY, Schlitt A, Nammas W, Airaksinen KE. Bivalirudin use during percutaneous coronary intervention in patients on chronic warfarin therapy. Thromb Res. 2014;133:695–6.

    Article  CAS  PubMed  Google Scholar 

  13. De Luca G, Verdoia M, Suryapranata H. Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials. Atherosclerosis. 2012;222:426–33.

    Article  PubMed  Google Scholar 

  14. Piccolo R, Galasso G, Capuano E, De Luca S, Esposito G, Trimarco B, Piscione F. Transradial versus transfemoral approach in patients undergoing percutaneous coronary intervention for acute coronary syndrome. A meta-analysis and trial sequential analysis of randomized controlled trials. PLoS One. 2014;9:e96127.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Valgimigli M, Gagnor A, Calabró P, Frigoli E, Leonardi S, Zaro T, Rubartelli P, Briguori C, Andò G, Repetto A, Limbruno U, Cortese B, Sganzerla P, Lupi A, Galli M, Colangelo S, Ierna S, Ausiello A, Presbitero P, Sardella G, Varbella F, Esposito G, Santarelli A, Tresoldi S, Nazzaro M, Zingarelli A, de Cesare N, Rigattieri S, Tosi P, Palmieri C, Brugaletta S, Rao SV, Heg D, Rothenbühler M, Vranckx P, Jüni P, MATRIX Investigators. Radial versus femoral access in patients with acute coronary syndromes undergoing invasive management: a randomised multicentre trial. Lancet. 2015;385:2465–76.

    Article  PubMed  Google Scholar 

  16. Ziakas AG, Koskinas KC, Gavrilidis S, Giannoglou GD, Hadjimiltiades S, Gourassas I, Theofilogiannakos E, Economou F, Styliadis I. Radial versus femoral access for orally anticoagulated patients. Catheter Cardiovasc Interv. 2010;76:493–9.

    Article  PubMed  Google Scholar 

  17. Michael TT, Alomar M, Papayannis A, Mogabgab O, Patel VG, Rangan BV, Luna M, Hastings JL, Grodin J, Abdullah S, Banerjee S, Brilakis ES. A randomized comparison of the transradial and transfemoral approaches for coronary artery bypass graft angiography and intervention: the RADIAL-CABG Trial (RADIAL Versus Femoral Access for Coronary Artery Bypass Graft Angiography and Intervention). JACC Cardiovasc Interv. 2013;6:1138–44.

    Article  PubMed  Google Scholar 

  18. Robertson L, Andras A, Colgan F, Jackson R. Vascular closure devices for femoral arterial puncture site haemostasis. Cochrane Database Syst Rev. 2016;3:CD009541.

    Google Scholar 

  19. Garg S, Serruys P. Benefits of and safety concerns associated with drug-eluting coronary stents. Expert Rev Cardiovasc Ther. 2010;8:449–70.

    Article  CAS  PubMed  Google Scholar 

  20. Windecker S, Meier B. Late coronary stent thrombosis. Circulation. 2007;116:1952–65.

    Article  PubMed  Google Scholar 

  21. Piccolo R, Pilgrim T, Heg D, Franzone A, Rat-Wirtzler J, Räber L, Silber S, Serruys PW, Jüni P, Windecker S. Comparative effectiveness and safety of new-generation versus early-generation drug-eluting stents according to complexity of coronary artery disease: a patient-level pooled analysis of 6,081 patients. JACC Cardiovasc Interv. 2015;8:1657–66.

    Article  PubMed  Google Scholar 

  22. Windecker S, Stortecky S, Stefanini GG, da Costa BR, Rutjes AW, Di Nisio M, Silletta MG, Maione A, Alfonso F, Clemmensen PM, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head S, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter D, Schauerte P, Sousa Uva M, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A, Kolh P, Jüni P. Revascularisation versus medical treatment in patients with stable coronary artery disease: network meta-analysis. BMJ. 2014;348:g3859.

    Article  PubMed  PubMed Central  Google Scholar 

  23. Stefanini GG, Baber U, Windecker S, Morice MC, Sartori S, Leon MB, Stone GW, Serruys PW, Wijns W, Weisz G, Camenzind E, Steg PG, Smits PC, Kandzari D, Von Birgelen C, Galatius S, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim HS, Valgimigli M, Kastrati A, Chieffo A, Mehran R. Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. Lancet. 2013;382:1879–88.

    Article  CAS  PubMed  Google Scholar 

  24. Wiebe J, Nef HM, Hamm CW. Current status of bioresorbable scaffolds in the treatment of coronary artery disease. J Am Coll Cardiol. 2014;64:2541–51.

    Article  CAS  PubMed  Google Scholar 

  25. Kleber FX, Rittger H, Bonaventura K, Zeymer U, Wöhrle J, Jeger R, Levenson B, Möbius-Winkler S, Bruch L, Fischer D, Hengstenberg C, Pörner T, Mathey D, Scheller B. Drug-coated balloons for treatment of coronary artery disease: updated recommendations from a consensus group. Clin Res Cardiol. 2013;102:785–97.

    Article  CAS  PubMed  Google Scholar 

  26. Valgimigli M, Patialiakas A, Thury A, McFadden E, Colangelo S, Campo G, Tebaldi M, Ungi I, Tondi S, Roffi M, Menozzi A, de Cesare N, Garbo R, Meliga E, Testa L, Gabriel HM, Airoldi F, Ferlini M, Liistro F, Dellavalle A, Vranckx P, Briguori C, ZEUS Investigators. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates. J Am Coll Cardiol. 2015;65:805–15.

    Article  CAS  PubMed  Google Scholar 

  27. Faxon DP, Eikelboom JW, Berger PB, Holmes DR, Bhatt DL, Moliterno DJ, Becker RC, Angiolillo DJ. Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. Thromb Haemost. 2011;106:571–84.

    Article  Google Scholar 

  28. Rubboli A, Faxon DP, Airaksinen KE, Schlitt A, Marín F, Bhatt DL, Lip GY. The optimal management of patients on oral anticoagulation undergoing coronary artery stenting. The 10th anniversary overview. Thromb Haemost. 2014;112:1080–7.

    Article  CAS  PubMed  Google Scholar 

  29. von Beckerath N, Taubert D, Pogatsa-Murray G, Schömig E, Kastrati A, Schömig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation. 2005;112:2946–50.

    Google Scholar 

  30. Lotrionte M, Biondi-Zoccai GG, Agostoni P, Abbate A, Angiolillo DJ, Valgimigli M, Moretti C, Meliga E, Cuisset T, Alessi MC, Montalescot G, Collet JP, Di Sciascio G, Waksman R, Testa L, Sangiorgi G, Laudito A, Trevi GP, Sheiban I. Meta-analysis appraising high clopidogrel loading in patients undergoing percutaneous coronary intervention. Am J Cardiol. 2007;100:1199–206.

    Article  CAS  PubMed  Google Scholar 

  31. Sarafoff N, Martischnig A, Wealer J, Mayer K, Mehilli J, Sibbing D, Kastrati A. Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation. J Am Coll Cardiol. 2013;61:2060–6.

    Article  CAS  PubMed  Google Scholar 

  32. Braun OÖ, Bico B, Chaudhry U, Wagner H, Koul S, Tydén P, Scherstén F, Jovinge S, Svensson PJ, Gustav Smith J, van der Pals J. Concomitant use of warfarin and ticagrelor as an alternative to triple antithrombotic therapy after an acute coronary syndrome. Thromb Res. 2015;135:26–30.

    Article  CAS  PubMed  Google Scholar 

  33. Lahtela H, Karjalainen PP, Niemelä M, Vikman S, Kervinen K, Ylitalo A, Puurunen M, Porela P, Nyman K, Hinkka-Yli-Salomäki S, Airaksinen KE. Are glycoprotein inhibitors safe during percutaneous coronary intervention in patients on chronic warfarin treatment? Thromb Haemost. 2009;102:1227–33.

    CAS  PubMed  Google Scholar 

  34. Agewall S, Cattaneo M, Collet JP, Andreotti F, Lip GY, Verheugt FW, Huber K, Grove EL, Morais J, Husted S, Wassmann S, Rosano G, Atar D, Pathak A, Kjeldsen K, Storey RF, ESC Working Group on C. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. Eur Heart J. 2013;34:1708–15.

    Article  PubMed  Google Scholar 

  35. Koskinas KC, Räber L, Zanchin T, Wenaweser P, Stortecky S, Moschovitis A, Khattab AA, Pilgrim T, Blöchlinger S, Moro C, Jüni P, Meier B, Heg D, Windecker S. Clinical impact of gastrointestinal bleeding in patients undergoing percutaneous coronary interventions. Circ Cardiovasc Interv. 2015;8:pii: e002053.

    Article  Google Scholar 

  36. Dewilde WJ, Oirbans T, Verheugt FW, Kelder JC, De Smet BJ, Herrman JP, Adriaenssens T, Vrolix M, Heestermans AA, Vis MM, Tijsen JG, van’t Hof AW, ten Berg JM, WOEST study investigators. Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial. Lancet. 2013;381:1107–15.

    Article  CAS  PubMed  Google Scholar 

  37. Rubboli A, Milandri M, Castelvetri C, Cosmi B. Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting. Cardiology. 2005;104:101–6.

    Article  PubMed  Google Scholar 

  38. Levine GN, Bates ER, Blankenship JC, Bailey SR, Bittl JA, Cercek B, Chambers CE, Ellis SG, Guyton RA, Hollenberg SM, Khot UN, Lange RA, Mauri L, Mehran R, Moussa ID, Mukherjee D, Nallamothu BK, Ting HH, American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines; Society for Cardiovascular Angiography and Intervention. 2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol. 2011;58:e44–122.

    Article  PubMed  Google Scholar 

  39. Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med. 2002;347:969–74.

    Article  CAS  PubMed  Google Scholar 

  40. van Es RF, Jonker JJ, Verheugt FW, Deckers JW, Grobbee DE. Antithrombotics in the secondary prevention of events in coronary thrombosis-2 (ASPECT-2). Lancet. 2002;360:109–13.

    Article  PubMed  Google Scholar 

  41. Hamon M, Lemesle G, Tricot O, Meurice T, Deneve M, Dujardin X, Brufau JM, Bera J, Lamblin N, Bauters C. Incidence, source, determinants, and prognostic impact of major bleeding in outpatients with stable coronary artery disease. J Am Coll Cardiol. 2014;64:1430–6.

    Article  PubMed  Google Scholar 

  42. Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H, Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY, Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;31(19):2369–429.

    Google Scholar 

  43. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation. 2007;115:2344–51.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Cardiology, Bern University Hospital, Bern, Switzerland

    Raffaele Piccolo, Thomas Pilgrim & Stephan Windecker

Authors
  1. Raffaele Piccolo
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Pilgrim
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Stephan Windecker
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Stephan Windecker .

Editor information

Editors and Affiliations

  1. Laboratory of Interventional Cardiology, Ospedale Maggiore, Bologna, Italy

    Andrea Rubboli

  2. Centre for Cardiovascular Sciences, University of Birmingham City Hospital, Birmingham, United Kingdom

    Gregory Y. H. Lip

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Piccolo, R., Pilgrim, T., Windecker, S. (2017). Atrial Fibrillation on Vitamin K Antagonist Undergoing Elective Percutaneous Coronary Intervention for Stable Effort Angina. In: Rubboli, A., Lip, G. (eds) Atrial Fibrillation and Percutaneous Coronary Intervention. Springer, Cham. https://doi.org/10.1007/978-3-319-42400-2_1

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-42400-2_1

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-42398-2

  • Online ISBN: 978-3-319-42400-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation